Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
Biogen(BIIB) stock is priced at $171.50, giving the company a market capitalization of 25.14B. It carries a P/E multiple of 16.03.
During the trading session on 2025-12-16, Biogen(BIIB) shares reached a daily high of $174.51 and a low of $169.52. At a current price of $171.50, the stock is +1.2% higher than the low and still -1.7% under the high.
Trading activity shows a volume of 2.38M, compared to an average daily volume of 1.81M.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $185.17 and a low of $110.04.
BIIB News
In early trading on Tuesday, shares of Strategy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.0%. Year to date,...
Biogen (BIIB) has been back in the spotlight after fresh data on two key neurology programs, zorevunersen for Dravet syndrome and subcutaneous lecanemab for Alz...
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data...
Analyst ratings
49%
of 35 ratingsMore BIIB News
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $156 from $149 and keeps an Equal Weight rating on the shares. The firm...
In recent days, Stoke Therapeutics and Biogen reported encouraging long-term Phase 1/2a and extension data for zorevunersen in Dravet syndrome, while Eisai and...
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More...
